Cargando…
Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
Debulking surgery followed by systemic chemotherapy—including three-weekly intravenous paclitaxel and carboplatin (GOG-158)—is the cornerstone for advanced epithelial ovarian, fallopian tubal, and peritoneal cancer (EOC) treatment. In this scenario, Federation of Gynecology and Obstetrics (FIGO) sta...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277645/ https://www.ncbi.nlm.nih.gov/pubmed/32443497 http://dx.doi.org/10.3390/ijerph17103523 |
_version_ | 1783543166725521408 |
---|---|
author | Chang, Chia-Hua Kuo, Hsiao-Li Chen, Tzu-Chien Weng, Chia-Sui Lim, Ling Huang, Wan-Chun Chang, Chih-Long Su, Tsung-Hsien Wang, Kuo-Gon Wang, Kung-Liahng Yang, Yuh-Cheng Chen, Jen-Ruei |
author_facet | Chang, Chia-Hua Kuo, Hsiao-Li Chen, Tzu-Chien Weng, Chia-Sui Lim, Ling Huang, Wan-Chun Chang, Chih-Long Su, Tsung-Hsien Wang, Kuo-Gon Wang, Kung-Liahng Yang, Yuh-Cheng Chen, Jen-Ruei |
author_sort | Chang, Chia-Hua |
collection | PubMed |
description | Debulking surgery followed by systemic chemotherapy—including three-weekly intravenous paclitaxel and carboplatin (GOG-158)—is the cornerstone for advanced epithelial ovarian, fallopian tubal, and peritoneal cancer (EOC) treatment. In this scenario, Federation of Gynecology and Obstetrics (FIGO) stage, cell types, completeness of surgery, lymph nodes (LN) status, adjuvant chemotherapy regimens, survival status, progression-free survival (PFS), and overall survival (OS) of 192 patients diagnosed as having stage IIIA1–IVB EOC over January 2008–December 2017 were analyzed retrospectively. Of them, 100 (52.1%) patients had been debulked optimally. Of all cases, 64.1% and 10.9% demonstrated serous and clear-cell carcinoma. Moreover, the FIGO stage, surgery completeness, and LN status affected recurrence/persistence and mortality (all p < 0.001). Clear cell carcinoma led to shorter survival than serous carcinoma (p = 0.002). Adjuvant chemotherapy regimens were divided into five main groups according to previous clinical trials. However, choice of chemotherapy failed to demonstrate significant differences in patient outcomes. Similar results were found in the sub-analysis of optimally debulked cases, except that intraperitoneal chemotherapy could reduce mortality risk when compared with GOG-158 (p = 0.042). Notably, retroperitoneal LN dissection in all cases or optimally debulked cases reduced risks of recurrence/persistence and mortality, and prolonged PFS and OS significantly (all p < 0.05). Without optimal debulking, LN dissection led to little improvement in outcomes. Various modified chemotherapy regimens did not prolong PFS and OS or reduce recurrence/persistence and mortality risks. LN dissection is strongly recommended to improve the completeness of surgery and patient outcome. Clear cell type has a poorer outcome than serous type, which requires more aggressive treatment and follow-up. |
format | Online Article Text |
id | pubmed-7277645 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72776452020-06-12 Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience Chang, Chia-Hua Kuo, Hsiao-Li Chen, Tzu-Chien Weng, Chia-Sui Lim, Ling Huang, Wan-Chun Chang, Chih-Long Su, Tsung-Hsien Wang, Kuo-Gon Wang, Kung-Liahng Yang, Yuh-Cheng Chen, Jen-Ruei Int J Environ Res Public Health Article Debulking surgery followed by systemic chemotherapy—including three-weekly intravenous paclitaxel and carboplatin (GOG-158)—is the cornerstone for advanced epithelial ovarian, fallopian tubal, and peritoneal cancer (EOC) treatment. In this scenario, Federation of Gynecology and Obstetrics (FIGO) stage, cell types, completeness of surgery, lymph nodes (LN) status, adjuvant chemotherapy regimens, survival status, progression-free survival (PFS), and overall survival (OS) of 192 patients diagnosed as having stage IIIA1–IVB EOC over January 2008–December 2017 were analyzed retrospectively. Of them, 100 (52.1%) patients had been debulked optimally. Of all cases, 64.1% and 10.9% demonstrated serous and clear-cell carcinoma. Moreover, the FIGO stage, surgery completeness, and LN status affected recurrence/persistence and mortality (all p < 0.001). Clear cell carcinoma led to shorter survival than serous carcinoma (p = 0.002). Adjuvant chemotherapy regimens were divided into five main groups according to previous clinical trials. However, choice of chemotherapy failed to demonstrate significant differences in patient outcomes. Similar results were found in the sub-analysis of optimally debulked cases, except that intraperitoneal chemotherapy could reduce mortality risk when compared with GOG-158 (p = 0.042). Notably, retroperitoneal LN dissection in all cases or optimally debulked cases reduced risks of recurrence/persistence and mortality, and prolonged PFS and OS significantly (all p < 0.05). Without optimal debulking, LN dissection led to little improvement in outcomes. Various modified chemotherapy regimens did not prolong PFS and OS or reduce recurrence/persistence and mortality risks. LN dissection is strongly recommended to improve the completeness of surgery and patient outcome. Clear cell type has a poorer outcome than serous type, which requires more aggressive treatment and follow-up. MDPI 2020-05-18 2020-05 /pmc/articles/PMC7277645/ /pubmed/32443497 http://dx.doi.org/10.3390/ijerph17103523 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chang, Chia-Hua Kuo, Hsiao-Li Chen, Tzu-Chien Weng, Chia-Sui Lim, Ling Huang, Wan-Chun Chang, Chih-Long Su, Tsung-Hsien Wang, Kuo-Gon Wang, Kung-Liahng Yang, Yuh-Cheng Chen, Jen-Ruei Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience |
title | Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience |
title_full | Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience |
title_fullStr | Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience |
title_full_unstemmed | Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience |
title_short | Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience |
title_sort | outcomes in advanced stage epithelial ovarian, fallopian tubal, and peritoneal cancer after primary surgery and adjuvant chemotherapies: a single-institute real-world experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277645/ https://www.ncbi.nlm.nih.gov/pubmed/32443497 http://dx.doi.org/10.3390/ijerph17103523 |
work_keys_str_mv | AT changchiahua outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT kuohsiaoli outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT chentzuchien outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT wengchiasui outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT limling outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT huangwanchun outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT changchihlong outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT sutsunghsien outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT wangkuogon outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT wangkungliahng outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT yangyuhcheng outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience AT chenjenruei outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience |